MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

Shots:

  • The P-I trial involves assessing MSB-0221 (ShA9) or vehicle applied topically on forearm skin in 54 adults with staphylococcus aureus-positive AD for 1week
  • The expression of mRNA for psmα was inhibited from S. aureus isolated from all participants while the correlation was observed within 7days b/w improvement in local eczema severity and killing of S. aureus
  • In general, the results showed the safety and potential benefits of bacteria to treat chronic skin diseases. Additionally, the company plans to conduct a P-II clinical trial that will evaluate MSB-0221 vs PBO in 150 patients over a 12wks. treatment period to treat AD

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Owler

The post MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis first appeared on PharmaShots.

Samsung Bioepis Initiates P-I Study of SB16 Proposed Biosimilar to Prolia (denosumab)

Shots:

  • The P-I study assesses the PK/PD, safety, tolerability of SB16 (denosumab) vs Prolia in 168 healthy male volunteers for osteoporosis. The study will be 3 arms study that involves dosing with SB16 either the EU or US-sourced Prolia
  • The proposed biosimilar references Amgen’s Prolia which was approved in 2010 for osteoporosis with a high risk of fracture
  • With the initiation, Samsung Bioepis continues to advance its biosimilar portfolio covering immunology, oncology, ophthalmology, and hematology

Click here ­to­ read full press release/ article | Ref: Samsung Bioepis | Image: Business Wire

The post Samsung Bioepis Initiates P-I Study of SB16 Proposed Biosimilar to Prolia (denosumab) first appeared on PharmaShots.